TORONTO, ONTARIO--(Marketwire - Feb. 14, 2011) - Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the appointment of Arthur L. Rosenthal to Chairman of its Board of Directors. 

Dr. Rosenthal is currently CEO of Cappella, Inc., a medical device company focused on coronary artery disease. He has previously served as Chairman and CEO of Labcoat Ltd. (Galway, Ireland), Senior VP and Chief Scientific Officer of Boston Scientific Corporation, VP of R&D for J&J Medical and VP R&D at CR Bard. He has served as Non Executive Director on Renovo, Ltd., UK, Labcoat Ltd., Ireland (Chairman, BOD) and is current a Non Executive Director, Cyberonics, Inc, Houston, Tx.

Dr. Rosenthal is a Fellow of AIMBE and holds an appointment as professor of practice, Department of Biomedical Engineering at Boston University. He received his Ph.D. in Biochemistry from the University of Massachusetts.

Dr. Rosenthal originally joined Interface Biologics Board in March, 2010. "We are delighted to have Art accept the position of Chairman of our Board of Directors," stated Tom Reeves, Interface Biologics' President & CEO. "The combination of his deep scientific knowledge and wealth of industry experience in both early stage and large multinational medical device companies is a tremendous asset to IBI. As we transition from materials research and development stage to product development and commercialization, his insights and direction will be invaluable. I look forward to his leadership as our new Chairman."

"I joined the Interface Biologics board last year because I was impressed with both their technology platforms and the management team and felt there was significant potential to address unmet needs in various medical device markets," commented Dr. Rosenthal. "Having worked for the last year with the IBI team, my fellow board members and the company's advisors, I am even more excited about these opportunities and am pleased to accept this Chairman position. I look forward to working with the team and industry partners to bring a variety of new products to market over the next few years." 

About Interface Biologics, Inc.

Interface Biologics is a commercial stage privately held company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. IBI's primary technology focus areas are anti-thrombogenic devices that reduce thrombosis without the need for heparin, anti-infective polymers, and programmable combination drug delivery devices. IBI, a University of Toronto spinoff, is now located at the MaRS Centre in Toronto, Canada. For more information about Interface Biologics, please visit

Contact Information: Hageman Communications
Julie Fotheringham